TIDMHEIQ
RNS Number : 7146O
HeiQ PLC
14 June 2022
14 June 2022
HeiQ Plc
("HeiQ" or "the Company")
C ommercial progress of HeiQ's Hygiene technologies across
multiple markets
HeiQ Plc (LSE:HEIQ), an established global brand in materials
and textile innovation that operates in high-growth markets, is
pleased to provide an update regarding the latest developments made
within its Hygiene technology business.
Following three strategic acquisitions in 2021, HeiQ
strengthened its Hygiene technology offering for healthcare,
facility management, coatings, antimicrobial plastics and textile
industries with a range of pre and probiotic, bio-based botanical
solutions, including its HeiQ Synbio technology. HeiQ now has one
of the most sustainable product ranges in the specialty hygiene
ingredients industry today.
A Review on Antimicrobial Resistance (AMR) commissioned by the
UK government estimates that by 2050, there will be 10 million
deaths globally per year due to antimicrobial resistance(1) . A
McKinsey study predicted that consumer focus on health and hygiene,
increased due to the recent pandemic, will endure in the long
term(2) . With this in mind, HeiQ has made it one of its business
imperatives to introduce effective and sustainable hygiene
solutions to healthcare facilities and across the markets it
operates in.
Strong independent validation of HeiQ Synbio cleaning
performance probiotic cleaning compared to conventional
disinfectants in preventing AMR in hospitals
-- A recent study by the Charité-Universitätsmedizin Hospital in
Berlin found that European hospitals could save EUR760 million a
year in medical costs related to HAI. through switching to
probiotic cleaning products such as HeiQ Synbio from traditional
disinfectants*.
-- HeiQ Synbio is proven to reduce AMR on hospital surfaces by
up to 99.9%(3) and to reduce incidences of HAI by up to 52%(4,5)
more effectively compared with traditional disinfectants.
-- As a result of using probiotic cleaning products such as HeiQ
Synbio, experts have demonstrated that hospitals could see a
reduction in costs associated with HAI by up to 75%(4) (.)
Positive implications on HeiQ's business
-- Following the publication of the results from the study in
Charité-Universitätsmedizin Hospital, HeiQ relaunched the extended
HeiQ Synbio range at Interclean Amsterdam, the world's largest
professional cleaning and hygiene exhibition, and held a seminar on
Spectacular Sanitization of Healthcare Facilities.
-- HeiQ expects the EU to follow these positive scientific
results and revise their facility management protocol guidelines
for hospitals which will accelerate the adoption of the study
recommendations. The Charité-Universitätsmedizin Hospital has
started purchasing HeiQ Synbio cleaners.
Commercial progress of HeiQ's broad Hygiene technologies across
multiple markets
-- HeiQ recently launched its innovative HeiQ Sanpure BIO, a
100% bio-based cleaner for facility management which enables less
frequent cleaning, and secured Engie Facility Management (part of
Engie SA, a French group with EUR60 bn turnover in 2019) as its
first adopter.
-- Greenspeed, HeiQ's main distributor to hospitals in Benelux
countries, has successfully launched two further new HeiQ Synbio
enabled products.
-- Helly Hansen (part of Mark's Canada, a company valued at
CA$1.2 bn) launched HeiQ Viroblock treated gowns with 99% reduction
claims for staphylococcus aureus & Sars-Cov-2 with a medical
device categorisation for hospitals in Canada.
-- Field trials conducted for Malteser International - an
international non-governmental humanitarian aid agency like the Red
Cross - demonstrates that HeiQ Sanpure Permanent Coating reduces
bacterial loads in ambulances by more than 50%. HeiQ has developed
critical healthcare surfaces.
-- HeiQ filed for a new HeiQ Synbio patent for textile
applications focusing on home textiles with anti-allergen and odour
control claims. A product launch is scheduled for Q3.
-- HeiQ and its long-term research partner Patagonia announced the launch of HeiQ Fresh MNT, a jointly-developed odour control textile technology based on renewably-sourced mint oil, complementing the Company's HeiQ Fresh family of sustainable odour management technologies consisting of mineral-based HeiQ Fresh HAX and bio-based HeiQ Fresh FFL.
HeiQ Group Co-Founder and CEO, Carlo Centonze said:
"I am delighted to report that momentum across our Hygiene
technology offering continues at an extremely high pace, with our
products independently proven to solve devastating issues which are
affecting people and medical facilities worldwide. The natural
ingredients used in our products mean that they are not only
capable of saving lives and costs, but that they can do so in a way
which does not harm the environment. This is causing governments to
reassess their guidance, which demonstrates the importance of our
findings and the scale of the issues we are solving.
"New contracts have been signed and brands brought on board, and
we have also launched new products and patent applications to
solidify the future potential of our product range, which is the
strongest and most sustainable in the specialty hygiene ingredients
industry. This is an exciting time for our Hygiene technology
business and with a strong pipeline in place, we look forward to
sharing future updates with our shareholders."
Footnotes
* Calculation based on 52% reduction of HAI incidence by HeiQ
Synbio cleaning performance probiotic cleaning(6) , impacting the
EUR1.46 Bn/year expenditure in AMR (2015-2050) and non-resistant
HAIs, estimated by the European Center for Disease Control
(ECDC)(7) and the Italian Ministry of Health(8)
1) Antimicrobial Resistance: Tackling a crisis for the health
and wealth of nations. The Review on Antimicrobial Resistance
Chaired by Jim O'Neill December 2014
2) McKinsey & Company, How COVID-19 is changing consumer
behavior - now and forever, 2020
3) Klassert, T. E. et al. Comparative analysis of surface
sanitization protocols on the bacterial community structures in the
hospital environment. Clin. Microbiol. Infect. 0, (2022).
4) Caselli, E. et al. Impact of a probiotic-based hospital
sanitation on antimicrobial resistance and HAI-associated
antimicrobial consumption and costs: a multicenter study. Infect.
Drug Resist. 12, 501-510 (2019).
5) Tarricone, R., Rognoni, C., Arnoldo, L., Mazzacane, S. &
Caselli, E. A Probiotic-Based Sanitation System for the Reduction
of Healthcare Associated Infections and Antimicrobial Resistances:
A Budget Impact Analysis. Pathogens 9, 502 (2020)
6) Caselli, E. et al. Impact of a probiotic-based hospital
sanitation on antimicrobial resistance and HAI-associated
antimicrobial consumption and costs: a multicenter study. Infect.
Drug Resist. 12, 501-510 (2019).
7) Infographic: Healthcare-associated infections - a threat to
patient safety in Europe. European Centre for Disease Prevention
and Control
https://www.ecdc.europa.eu/en/publications-data/infographic-healthcare-associated-infections-threat-patient-safety-europe
(2018).
8) Salute, M. della. Antibiotico-resistenza nel settore umano.
https://www.salute.gov.it/portale/antibioticoresistenza/dettaglioContenutiAntibioticoResistenza.jsp?lingua=italiano&id=5282&area=antibiotico-resistenza&menu=vuoto&tab=1
.
For further information, please visit www.heiq.com/investors or
contact:
HeiQ Plc
Carlo Centonze (CEO) +41 56 250 68 50
H eiQ Investors Relations Service Desk https://heiq.atlassian.net/servicedesk
/customer/portal/11/group/22/create/92
----------------------------------------
Cenkos Securities plc (Joint Broker) +44 (0) 207 397
Stephen Keys / Callum Davidson 8900
----------------------------------------
SEC Newgate (Media Enquiries) +44 (0) 20 3757
Elisabeth Cowell / Axaule Shukanayeva 6882
/ Molly Gretton HeiQ@secnewgate.co.uk
----------------------------------------
About HeiQ
HeiQ Plc is a purpose-led IP creator for novel materials. It
develops and commercialises technologies that make textiles,
surfaces and materials more hygienic, protective, comfortable and
resource efficient. And critically, they make them more sustainable
too.
HeiQ offers technologies in 4 main functions to customers and
consumers and delivers them in 4 forms (our "4x4" approach). It
sells these technologies in a range of different forms - either as
ingredients, materials, finished goods or on a trademark licensing
basis. Its added functionalities provide product-developers with a
valuable USP, which means that HeiQ's end users include over 300
major brands.
During its 17-year history, HeiQ has built long-standing
relationships with clients all over the world and secured an
established position in the textile sector. In recent years, it has
expanded its offerings to other industries to also address material
innovations in healthcare, water treatment, industrial laundry,
detergents, paints and coatings, plastics and packaging.
HeiQ employs over 300 people, based in 14 offices, 8 R&D
hubs and 7 manufacturing facilities around the world. Over 20
distributors complete its global presence to serve over 50
countries.
, the news service of the London Stock Exchange. RNS is approved by
the Financial Conduct Authority to act as a Primary Information
Provider in the United Kingdom. Terms and conditions relating to
the use and distribution of this information may apply. For further
information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCGPUPCQUPPGQW
(END) Dow Jones Newswires
June 14, 2022 02:00 ET (06:00 GMT)
Heiq (LSE:HEIQ)
Historical Stock Chart
From Nov 2024 to Dec 2024
Heiq (LSE:HEIQ)
Historical Stock Chart
From Dec 2023 to Dec 2024